EPI-743
Based on 1 Customer Validation
EPI-743 (Vatiquinone; α-Tocotrienol quinone; PTC-743; NCT04378075) is a potent cellular oxidative stress protectant, inhibits ferroptosis in cells, which could be used for the study for mitochondrial diseases. EPI-743 is a synthetic analog of vitamin E with oral activity, targets repletion of reduced intracellular glutathione.
For research use only. We do not sell to patients.
- Purity: 98.06%
- CAS No.: 1213269-98-7
- Formula: C29H44O3
- Molecular Weight:440.66
-
Storage:Pure form -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
Bioactive Compound Library Max
HY-L181
-
Bioactive Compound Library
HY-L001
-
Metabolism/Protease Compound Library
HY-L012
-
Stem Cell Signaling Compound Library
HY-L017
-
Clinical Compound Library
HY-L026
-
Anti-Aging Compound Library
HY-L034
-
Drug Repurposing Compound Library
HY-L035
-
Oxygen Sensing Compound Library
HY-L045
-
Ferroptosis Compound Library
HY-L051
-
Orally Active Compound Library
HY-L061
-
Glutamine Metabolism Compound Library
HY-L064
-
Anti-Cancer Metabolism Compound Library
HY-L083
-
Anti-Parkinson's Disease Compound Library
HY-L085
-
Neurodegenerative Disease-related Compound Library
HY-L086
-
Mitochondria-Targeted Compound Library
HY-L089
-
Glucose Metabolism Compound Library
HY-L092
-
Rare Diseases Drug Library
HY-L102
-
Cuproptosis Compound Library
HY-L133
-
Metabolic Enzyme Compound Library
HY-L146
-
Cell Death Library
HY-L162
-
Drug Repurposing Compound Library Plus
HY-L035P
-
Clinical Compound Library Plus
HY-L026P
-
Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library
HY-L199
-
High-Throughput Bioactive Compound Library
HY-L205
Biological Activity
Mitochondria[1].
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| Fibroblast | EC50 |
24 nM
Compound: ATQ3
|
Cytoprotectant activity against L-buthionine-(S,R)-sulfoximine-induced cell death in Friedreich ataxia patient fibroblasts assessed as increase of cell viability
Cytoprotectant activity against L-buthionine-(S,R)-sulfoximine-induced cell death in Friedreich ataxia patient fibroblasts assessed as increase of cell viability
|
[PMID: 21600768] |
| Fibroblast | EC50 |
30 nM
Compound: ATQ3
|
Cytoprotectant activity against L-buthionine-(S,R)-sulfoximine-induced cell death in Leigh syndrome patient fibroblasts assessed as increase of cell viability
Cytoprotectant activity against L-buthionine-(S,R)-sulfoximine-induced cell death in Leigh syndrome patient fibroblasts assessed as increase of cell viability
|
[PMID: 21600768] |
Ferroptosis is a form of iron- and lipid-dependent regulated cell death associated with glutathione depletion and production of lipid peroxides by lipoxygenase enzymes.
EPI-743 prevents RSL3-induced ferroptosis in PCH6 patient fibroblasts with mean EC50 potency values of 17.3-21.8 nM[3].
EPI-743 (37, 111, 333 nM; 24 h) exhibits prevention of BODIPY 581/591 C11 lipid oxidation[3].
EPI-743 (0.1 nM-1 mM; 48 h) potently prevents ferroptosis induced by RSL3 (2 μM), FeC (100 μM), BSO (50 μM)[3].
EPI-743 (1 μM, 3 h) is reduced to EPI-743 hydroquinone (EPI-743-HQ) in PCH6 patient fibroblasts, and EPI-743-HQ (0.1-100 μM; 30 min) inhibits human 15-LO enzyme activity with 20% inhibition at 100 μM, and IC50 is 4.4 μM[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Primary fibroblasts and B-lymphocytes
-
Concentration:0-1 mM
-
Incubation Time:48 hours
-
Result:Inhibited RSL3-mediated ferroptotic cell death in B-lymphocytes in a dose-dependent manner.
Restored viability to levels comparable with untreated cells, indicating complete rescue.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 1213269-98-7
-
Appearance Liquid (Density: 0.978±0.06 g/cm3)
-
Molecular Weight 440.66
-
Formula C29H44O3
-
Color Light yellow to yellow
-
SMILES
O=C1C(CC[C@](C)(O)CC/C=C(C)/CC/C=C(C)/CC/C=C(C)\C)=C(C)C(C(C)=C1C)=O
-
Synonyms
α-Tocotrienol quinone; PTC-743; Vatiquinone; NCT04378075
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Pure form -20°C 3 years In solvent -80°C 6 months -20°C 1 month
Solvent & Solubility
DMSO : 100 mg/mL (226.93 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (5.67 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (270 KB)
-
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
-
Handling Instructions (2659 KB)
References
[1]. Kouga T, et al. Japanese Leigh syndrome case treated with EPI-743. Brain Dev. 2018 Feb;40(2):145-149. Brain Dev. 2018 Feb;40(2):145-149. [Content Brief]
[2]. Avula S, et al. Treatment of Mitochondrial Disorders. Curr Treat Options Neurol. 2014. 16:292.
[3]. Kahn-Kirby AH, et al. Targeting ferroptosis: A novel therapeutic strategy for the treatment of mitochondrial disease-related epilepsy. PLoS One. 2019 Mar 28;14(3):e0214250. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.2693 mL | 11.3466 mL | 22.6932 mL | 56.7331 mL |
| 5 mM | 0.4539 mL | 2.2693 mL | 4.5386 mL | 11.3466 mL | |
| 10 mM | 0.2269 mL | 1.1347 mL | 2.2693 mL | 5.6733 mL | |
| 15 mM | 0.1513 mL | 0.7564 mL | 1.5129 mL | 3.7822 mL | |
| 20 mM | 0.1135 mL | 0.5673 mL | 1.1347 mL | 2.8367 mL | |
| 25 mM | 0.0908 mL | 0.4539 mL | 0.9077 mL | 2.2693 mL | |
| 30 mM | 0.0756 mL | 0.3782 mL | 0.7564 mL | 1.8911 mL | |
| 40 mM | 0.0567 mL | 0.2837 mL | 0.5673 mL | 1.4183 mL | |
| 50 mM | 0.0454 mL | 0.2269 mL | 0.4539 mL | 1.1347 mL | |
| 60 mM | 0.0378 mL | 0.1891 mL | 0.3782 mL | 0.9456 mL | |
| 80 mM | 0.0284 mL | 0.1418 mL | 0.2837 mL | 0.7092 mL | |
| 100 mM | 0.0227 mL | 0.1135 mL | 0.2269 mL | 0.5673 mL |
EPI-743 Related Classifications
HY-16772 Related Classifications
Powered by Bioz